The National Institutes of Health’s decision to reject a petition asking the agency to use “march-in rights” on the patent for Astellas Pharma Inc./Medivation Inc.’s prostate cancer drug Xtandi (enzalutamide) without even holding a hearing takes one wild card approach to attacking drug prices off the table – at least until the end of the Obama Administration.
Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment petitioned